You are here: Industry Insights > Rylaze

News List

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458 firstwordpharma
July 22, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze™(asparaginase erwinia chrysanthemi (recombinant)-rywn), also known as JZP458.
FDA Approves Treatment Regimen for Most Prevalent Childhood Cancer americanpharmaceuticalreview
July 05, 2021
The FDA approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the ...
Jazz Pharma’s blood cancer therapy Rylaze wins US approval pharmatimes
July 02, 2021
The US Food and Drug Administration has approved Dublin-based Jazz Pharmaceutical’s Rylaze for the treatment of two blood cancers – acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).
FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma drugs
July 02, 2021
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen.
FDA Approves Component of Treatment Regimen for Most Common Childhood Cancer fda.gov
July 02, 2021
Today, the U.S. Food and Drug Administration approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients.